Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078249 | 0.86 | PARP1 (0.45) | LIPGPARP1PARP2ALDH1A1 | |
| SCHEMBL6077535 | 0.84 | LIPG (0.51) | LIPGPARP1PARP2ALDH1A1 | |
| SCHEMBL6077393 | 0.84 | LIPG (0.39) | LIPGPARP1PARP2ALDH1A1 | |
| SCHEMBL6078320 | 0.82 | LIPG (0.38) | LIPGPARP1NPC1ALDH1A1RAB9A | |
| SCHEMBL6076462 | 0.80 | LIPG (0.37) | LIPGPARP1PARP2 | |
| SCHEMBL6077749 | 0.78 | KDM4E (0.41) | LIPGPARP1KDM1AALDH1A1 | |
| SCHEMBL6078915 | 0.77 | LIPG (0.48) | LIPGPARP1PARP2NPC1ALDH1A1 | |
| SCHEMBL6077032 | 0.76 | PARP1 (0.38) | LIPGPARP1PARP2 | |
| SCHEMBL6079318 | 0.75 | SMN1; SMN2 (0.38) | LIPGPARP1PARP2ALDH1A1 | |
| SCHEMBL6076770 | 0.75 | KMT2A (0.53) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | LIPG 2895/4885PARP1 65/4885ARG1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.